Eldelumab

Eldelumab (alternative identifier BMS-936557[1]) is a fully human monoclonal antibody (type IgG1 kappa)[2] that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10)[2][3] designed for the treatment of Crohn's disease and ulcerative colitis.[4]

Eldelumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCXCL10/IP-10
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC6502H10024N1736O2026S48
Molar mass146.5 kg/mol g·mol−1

This drug was developed by Bristol-Myers Squibb and Medarex[5]

References
  1. Sandborn, William J.; Colombel, Jean-Frédéric; Ghosh, Subrata; Sands, Bruce E.; Dryden, Gerald; Hébuterne, Xavier; Leong, Rupert W.; Bressler, Brian; Ullman, Thomas (2016-04-01). "Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study". Journal of Crohn's and Colitis. 10 (4): 418–428. doi:10.1093/ecco-jcc/jjv224. ISSN 1873-9946. PMC 4946756. PMID 26721935.
  2. "Anti-CXCL10 Therapeutic Antibody (eldelumab) - Creative Biolabs". www.creativebiolabs.net. Retrieved 2017-03-24.
  3. Sandborn, William J.; Colombel, Jean-Frédéric; Ghosh, Subrata; Sands, Bruce E.; Dryden, Gerald; Hébuterne, Xavier; Leong, Rupert W.; Bressler, Brian; Ullman, Thomas (2016-04-01). "Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study". Journal of Crohn's & Colitis. 10 (4): 418–428. doi:10.1093/ecco-jcc/jjv224. ISSN 1876-4479. PMC 4946756. PMID 26721935.
  4. Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab, American Medical Association.
  5. "Eldelumab - AdisInsight". adisinsight.springer.com. Retrieved 2017-03-24.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.